• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Valeo Pharma signs Canadian commercialization deal with Novartis

March 29, 2021 By Sean Whooley

Valeo Pharma NovartisValeo Pharma announced today that it entered into a commercialization and supply agreement with Novartis Canada for its asthma therapies.

Montreal-based Valeo’s deal is to offer Canadian commercialization efforts for two asthma therapies: Enerzair Breezhaler (indacaterol as acetate, glycopyrronium as bromide and mometasone furoate, and Atectura Breezhaler (indacaterol as acetate and mometasone fuorate).

Under the agreement, Valeo will be responsible for both the medical and commercial activities for both Breezhaler asthma treatments over the course of an initial eight-year period.

Both the Enerzair and Atectura formulations are once-daily therapeutics available in the hydrofluoroalkane/chlorofluorocarbon (HFA/CFC)-free Breezhaler device.

“We are extremely pleased to be partnering with Novartis to launch these two asthma drugs in the coming weeks. Commercializing Enerzair Breezhaler and Atectura Breezhaler will immediately position Valeo as one of the leading Canadian respiratory companies providing first in-class and best in-class asthma therapies. The Canadian asthma maintenance market exceeds $700M annually,” Valeo CEO Steve Saviuk said in a news release. “This partnership is perfectly aligned with Valeo’s vision and mission of building a Canadian anchor pharmaceutical company by driving therapeutic innovation to patients in need. We look forward to building a long and mutually beneficial relationship with Novartis that will help both companies fulfill their respective missions.” 

“This agreement with Valeo Pharma fits with our overall strategy to provide innovative medicines that have the potential to improve health outcomes,” added Novartis Canada head of country pharma organization Andrea Marazzi. “Valeo’s commitment and focus to bring Enerzair® Breezhaler and Atectura Breezhaler to Canadians, combined with our strong respiratory experience, brings a solution that will help make asthma control a more attainable goal for some Canadians.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Novartis, Valeo Pharma

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS